Welcome to the Investor Relations pages for Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need.
Midatech is commercialising oncology treatment and supportive care products via its US Commercial Organisation, Midatech Pharma US. In Europe, Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of Cancer, Endocrine Disorders such as Diabetes, and Immunotherapy for autoimmune diseases.
Midatech’s strategy is to expand it US commercial arm as well as develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.
Midatech Pharma Group is incorporated in England and Wales, with global headquarters in the United Kingdom and a fully integrated commercial subsidiary based in the United States.
Midatech’s ordinary shares are traded on the Alternative Investment Market (AIM) of the London Stock Exchange under the ticker symbol MTPH (ISIN number GB00BRTL9B63). Midatech’s American Depositary Shares trade on the NASDAQ Capital Market in the United States under the symbol MTP (CUSIP No. 59564R 104).
The information disclosed in these pages is in accordance with Rule 26 of the Aim Rules. The investor site was most recently updated on 14 September 2018.